9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 164

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: OS,  PFS,  Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])., ORR

Interventions: Gemcitabine, Ramucirumab

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Primary Purpose: Treatment

Primary Completion Date: December 22, 2019

Completion Date: December 22, 2020

Last  Posted Date: February 28, 2019

Location: Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

Website Link: https://ClinicalTrials.gov/show/NCT03560973

Was this article helpful?
Dislike 0